FDA approves Gemtesa for overactive bladder in men with benign prostatic hyperplasia
Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...
Medscape1d
Percutaneous Tibial Nerve Stimulation for the Treatment of Overactive Bladder
An important question is how PTNS compares with the established alternatives for the treatment of overactive bladder. Established treatments would include non-pharmacologic measures such as ...
Ask Dr James: Why do I keep needing the toilet in the night?
In his regular column, Dr James Le Fanu answers your questions. This week, a reader asks whether her overactive bladder ...
Daily Mail5d
How to end the tyranny of an overactive bladder: Amid concern over the dementia risk of a top incontinence drug, our top doctor's guide on what YOU can do instead
Unhappily, oxybutynin hydrochloride, tolterodine tartrate and solifenacin succinate – the three linked to dementia – are considered the most effective drugs for treating overactive bladder.
Rolling Out9d
What treatments are available for bladder control?
Modern treatment approaches offer numerous options ... Acupuncture shows promise in reducing overactive bladder symptoms and stress incontinence. However, results vary among individuals, and more ...
HealthDay on MSN7d
FDA Approves Gemtesa for Overactive Bladder in Men With BPH
Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...
Overactive Bladder Treatment Market Future Trends, Business Growth, Size, Share, Segmentation, Dynamics and Forecast
Overactive Bladder Treatment market in terms of revenue was estimated to be worth $3.5 billion in 2022 and is poised to reach ...
tyla3h
Doctors reveal how often is normal to get up during the night to pee and when you should worry
There are a number of reasons why you have to get up in the middle of the night to go for a wee, but how often is normal?
Imbrium Therapeutics Announces Results of a Sunobinop Phase 1b Study in Patients With Overactive Bladder Syndrome
Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...